Simon Page, PhD

Global Medical Affairs Director
Ipsen, London, United Kingdom, United Kingdom

Poster(s):

• 400 Section - A randomized, double-blind, head-to-head, crossover study comparing the clinical safety and efficacy of abobotulinumtoxinA with onabotulinumtoxinA when treating adults with upper limb spasticity
  Wednesday, May 20, 2026

  6:00 PM - 7:30 PM PT

• 400 Section - A retrospective cohort study assessing persistence to botulinum toxin A and factors associated with discontinuation
  Wednesday, May 20, 2026

  6:00 PM - 7:30 PM PT

• 300 Section - Sensitivity and specificity of the Post-stroke Spasticity Monitoring Questionnaire (PSMQ) for remote monitoring of spasticity development: Interim analysis from an ongoing epidemiological study
  Tuesday, May 19, 2026

  6:00 PM - 7:30 PM PT